|Day Low/High||23.78 / 25.30|
|52 Wk Low/High||9.04 / 28.75|
The market action is creating some mis-pricing in individual stocks. But if the market stays under pressure then stock picking will remain difficult.
-- Increased quarterly revenue by 43% and volume by 52% year-over-year --
Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.
We saw some minor positives in Thursday's decline, so let's dive into them and what they mean.
Citron analyst sees 'indestructible moat' around genetic-testing company's business.
- Designed to overcome barriers to testing and connect patients to earlier diagnosis and treatments -
SAN FRANCISCO, July 23, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2019 financial results on Tuesday, August 6, 2019 and will host a conference call...
I don't expect to see the bears and shorts press too hard right now but there isn't going to be much upside momentum.
Biotech adds 4% to $23.44 after Left, who's better known for his short positions, argues it can go to $100 a share.
-- Jungla Applies Advanced Modeling Technologies, Including Artificial Intelligence, to Enhance Scalable Genetic Variant Interpretation --
Investors in Invitae Corp saw new options begin trading this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVTA options chain for the new August 16th contracts and identified one put and one call contract of particular interest.
SAN FRANCISCO, June 20, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted time-based and development milestone-based restricted stock units ("RSUs") to new employees who joined...
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Invitae Corp , where a total volume of 6,067 contracts has been traded thus far today, a contract volume which is representative of approximately 606,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 49.2% of NVTA's average daily trading volume over the past month, of 1.2 million shares.
-- Singular Bio's Technology Designed to Enable High-Quality, Low-Cost Genetic Testing at Scale to Expand Access to Non-Invasive Prenatal Screening --
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and Invitae Corporation (NYSE: NVTA), a leader in medical genetics, today announced a...
-Genetic testing can identify causes of rare, progressive eye disorders-
-- Provides high-quality, affordable, clinician-guided genetic testing to inform healthcare decisions --
- Data to be presented at the American Society of Clinical Oncology Annual Meeting -
Horizon Therapeutics plc (Nasdaq: HZNP) in partnership with Invitae Corporation (NYSE: NVTA) today announced a new urea cycle disorder (UCD) genetic testing program designed to speed diagnosis and enable physicians to offer genetic testing at no-charge to...
SAN FRANCISCO, May 22, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae will present at the 2019 William Blair Growth Stock...
SAN FRANCISCO, May 15, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the UBS Global Healthcare...
Results from one of the largest datasets in uterine cancer presented at The American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting
Investors in Invitae Corp saw new options begin trading today, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
SAN FRANCISCO, April 23, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019 and will host a conference call and webcast...
Confirmatory FH Genetic Testing and Counseling Offered through Invitae and Genome Medical
- Data presented at The American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting -
Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'
In recent trading, shares of Invitae Corp have crossed above the average analyst 12-month target price of $22.96, changing hands for $22.97/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.